Microarray analysis of retinal gene expression in Egr-1 knockout mice

Ruth Schippert, Frank Schaeffel, Marita Pauline Feldkaemper

Institute for Ophthalmic Research, Section of Neurobiology of the Eye, University Eye Hospital Tuebingen,Tuebingen, Germany

Purpose: We found earlier that 42 day-old Egr-1 knockout mice had longer eyes and a more myopic refractive error compared to their wild-types. To identify genes that could be responsible for the temporarily enhanced axial eye growth, a microarray analysis was performed in knockout and wild-type mice at the postnatal ages of 30 and 42 days.

Methods: The retinas of homozygous and wild-type Egr-1 knockout mice (Taconic, Ry, Denmark) were prepared for RNA isolation (RNeasy Mini Kit, Qiagen) at the age of 30 or 42 days, respectively (n=12 each). Three retinas were pooled and labeled cRNA was made. The samples were hybridized to Affymetrix GeneChip Mouse Genome 430 2.0 Arrays. Hybridization signals were calculated using GC-RMA normalization. Genes were identified as differentially expressed if they showed a fold-change (FC) of at least 1.5 and a p-value <0.05. A false-discovery rate of 5% was applied. Ten genes with potential biologic relevance were examined further with semiquantitative real-time RT–PCR.

Results: Comparing mRNA expression levels between wild-type and homozygous Egr-1 knockout mice, we found 73 differentially expressed genes at the age of 30 days and 135 genes at the age of 42 days. Testing for differences in gene expression between the two ages (30 versus 42 days), 54 genes were differentially expressed in wild-type mice and 215 genes in homozygous animals. Based on three networks proposed by Ingenuity pathway analysis software, nine differently expressed genes in the homozygous Egr-1 knockout mice were chosen for further validation by real-time RT–PCR, three genes in each network. In addition, the gene that was most prominently regulated in the knockout mice, compared to wild-type, at both 30 days and 42 days of age (protocadherin beta-9 [Pcdhb9]), was tested with real-time RT–PCR. Changes in four of the ten genes could be confirmed by real-time RT–PCR: nuclear prelamin A recognition factor (Narf), oxoglutarate dehydrogenase (Ogdh), selenium binding protein 1 (Selenbp1). Except for Pcdhb9, the genes whose mRNA expression levels were validated were listed in one of the networks proposed by Ingenuity pathway analysis software. In addition to these genes, the software proposed several key-regulators which did not change in our study: retinoic acid, vascular endothelial growth factor A (VEGF-A), FBJ murine osteosarcoma viral oncogene homolog (cFos), and others.

Conclusions: Identification of genes that are differentially regulated during the development period between postnatal day 30 (when both homozygous and wild-type mice still have the same axial length) and day 42 (where the difference in eye length is apparent) could improve the understanding of mechanisms for the control of axial eye growth and may lead to potential targets for pharmacological intervention. With the aid of pathway-analysis software, a coarse picture of possible biochemical pathways could be generated. Although the mRNA expression levels of proteins proposed by the software, like VEGF, FOS, retinoic acid (RA) receptors, or cellular RA binding protein, did not show any changes in our experiment, these molecules have previously been implicated in the signaling cascades controlling axial eye growth. According to the pathway-analysis software, they represent links between several proteins whose mRNA expression was changed in our study.

Myopia is becoming an increasing problem, especially in industrial nations. It is widely believed that both hereditary and environmental factors contribute to the development of myopia. Several molecules have already been identified in the retina that appear to be involved in the visual control of axial elongation of the eye (e.g., dopamine [1-3], retinoic acid [4-6], nitric oxide [7-9], vasoactive intestinal polypeptide [10-12]). Another factor that was found to be involved was the transcription factor Egr-1 (early growth response protein-1), the mammalian ortholog to the avian protein ZENK (also called Tis8, Nf-6, Kro×−24, Zif268 in other species). By means of immunocytochemistry it was initially found that the number of ZENK-immunoreactive amacrine cells in the retina of chicks is increased under conditions that lead to a reduction in eye growth (myopic defocus, recovery of myopia) and decreased under conditions that enhance ocular growth (hyperopic defocus, form-deprivation). These changes were most prominent and distinct in a specific subset of amacrine cells, the glucagon-containing amacrine cells [13,14]. Recently, this bi-directional response was detected by means of immunohistochemistry in another glucagon-containing cell type of the chicken retina as well, the so-called...
bullwhip-cells [15]. Moreover, a downregulation of Egr-1 mRNA in total retinal tissue was found in mice after short periods of form-deprivation [16]. All of these experiments suggested that Egr-1 (ZENK) is an important factor in controlling eye growth, at least in some animal models for myopia. However, it should be noticed that mRNA levels of Egr-1 in the total retina of chicks do not seem to show this bidirectional response consistently. Although ZENK mRNA levels are upregulated in total retinal samples within one hour after diffuser removal of former form-deprived chicks (recovery of myopia) [17], treatment with both minus lenses and plus lenses for one day reduced the amount of ZENK mRNA in the total retina of chicks in both cases, suggesting that the role of Egr-1 is complex and may vary among special cell types [18,19]. Unfortunately, no study is available that investigated the time course of Egr-1 mRNA changes in detail. Therefore, current knowledge about the regulation of Egr-1 during increased or decreased eye growth is still limited.

Studies on Egr-1 knockout mice were in line with the hypothesis that Egr-1 has a function in the regulation of eye growth. Homozygous knockout mice, lacking functional Egr-1 protein, developed relative axial myopia at the age of 42 and 56 days (compared to heterozygous and wild-type Egr-1 knockout mice [20]). The difference in axial length declined with increasing age, but the differences in the refractive state persisted. Paraxial schematic eye modeling suggested that other optical elements, possibly the lens, had also changed in the Egr-1 knockout mice. This is not surprising, given that Egr-1 was absent not only from retinal amacrine cells but from all cells of the body. The effect of lacking Egr-1 protein should have long-ranging effects on other cells in the retina, eye, and the autonomic nervous system or the endocrine system.

Egr-1 is known to have a function in a variety of biologic processes (e.g., cell proliferation [21], brain plasticity and learning [22], apoptosis [23]) and several target genes of Egr-1 have already been identified. Egr-1-overexpression in synovial fibroblasts leads to an increased expression of collagen type 1 and of tissue inhibitor of metalloproteinases type 1 and 3 (TIMP1 and TIMP3) [24]. Since the induction of myopia is associated with scleral thinning through reduced accumulation of collagen and increased degradation of scleral tissue [25-27], the reduction of Egr-1-stimulated collagen expression and the reduced inhibition of degrading enzymes (such as the matrix-metalloproteinases that are repressed by TIMPs) that could take place in animals without functional Egr-1 protein, could explain the myopic phenotype of these mice. Other genes that are already known to be influenced by Egr-1 are for instance platelet-derived growth factor-A and -B (PDGF-A and -B) [28,29], basic fibroblast growth factor (bFGF) [30] and transforming growth factor-beta (TGF-β) [31].

Because of the complex role of Egr-1 in the regulation of various other proteins, and the differences in axial eye length between the Egr-1 knockout mice and the wild-type mice, we have studied the role of Egr-1 in the retina in more detail. Retinal samples of Egr-1 knockout and wild-type mice at the age of 30 days (no difference in axial eye length yet) and 42 days (already a difference in axial eye length of 59 µm) were compared regarding their mRNA expression changes, both between the two genotypes and within the same genotype between the two age groups.

**METHODS**

**Animals:** Experiments were conducted in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and were approved by the University Commission for Animal Welfare. Egr-1 knockout mice, generated on C57/BL6 background, were purchased from Taconic (Ry, Denmark) and bred in the animal facilities of the institute after a breeding permission was obtained from the company. Since female homozygous knockout mice are sterile because of a deficiency of luteinizing hormone-beta (which is due to the lack of Egr-1 [32]), only heterozygous females were bred. Animals were housed in standard cages with their littersmates under a 12 h light/dark cycle with unrestricted access to water and food pellets. Illumination was provided by standard fluorescent lamps and was approximately 200 lx. Standard PCR was performed to determine genotype (specific primer sequences provided by Taconic) and gender (with primers designed for the gene encoding the sex-determining region Y represents as SRY).

Male mice were killed by an overdose of diethyl ether at the mean age of 30 days (p29-p31) or 42 days (p41-p43). Eyes were enucleated and retinas were prepared carefully to ensure that the samples were not contaminated with retinal pigment epithelium. Tissue was snap-frozen in liquid nitrogen. The retinas of 12 homozygous Egr-1 knockout mice (hm) and 12 wild-type mice (wt) of the same strain were prepared for both time points (48 animals in total). Three single retinas from different mice were then pooled to obtain four samples per group (wt/30, wt/42, hm/30, hm/42), and RNA was isolated using the RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions.

**Microarray:** Quality check of RNA, cDNA synthesis and labeling and the actual microarray analysis was performed by the Affymetrix Resource Facility at the University of Tuebingen. The quality of total RNA was monitored by Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA) following the manufacturer's instructions. Generation of double-stranded cDNA, preparation and labeling of cRNA, hybridization to 430 2.0 Mouse Genome Arrays (Affymetrix, Santa Clara, CA), washing, and scanning were performed according to the standard Affymetrix protocol. Scanning and analysis were performed using the Affymetrix Microarray
Suite Software (version 5.0) and the signal intensities were analyzed using ArrayAssist 5.5.1 (Stratagene, La Jolla, CA).

Data were normalized using the GC-RMA normalization method which uses the GC content of the probes in normalization with RMA (Robust Multi-Array). To correct for multiple testing, a false-discovery rate of 5% was applied. All comparisons of mRNA expression levels between the groups were performed using un-paired t-tests. Genes were identified as differentially expressed if they showed a fold-change (FC) of at least 1.5 with a p value lower than 0.05. Fold change was calculated by dividing the experimental value (lens-treated, t) by the control value (untreated control, c). If the relative signal intensity of the control was higher than the intensity of the treated samples, the negative reciprocal was calculated (-c/t). A fold change of 1 or −1 therefore indicates no change, while a fold change of 2 equals a doubling in product, and a fold change of −2 equals a halving in transcript abundance.

The data discussed in this publication have been deposited in the National Center for Biotechnology Information (NCBI’s) Gene Expression Omnibus (GEO) and are accessible through GEO Series accession number GSE16974.

Pathway analysis: The list of differently expressed genes was subjected to a subsequent post-analysis task to find the main biologic processes associated with the experimental system. The “Ingenuity Pathways Analysis” Software 5.0 (IPA, Ingenuity Systems) was applied to elucidate putative pathways associated with the gene expression changes in the retinas of the Egr-1 knockout mice between the age of 30 days and 42 days. For this purpose, 215 genes which were classed as “differently expressed,” e.g., those whose retinal mRNA expression in the knockout mice at p30 was significantly different from the expression at p42, were analyzed and theoretical networks and pathways were computed. The IPA is a manually curated database of functional interactions and contains previously published findings from peer-reviewed publications. Interactions between proteins and molecules in the proposed networks are therefore supported by published information which is associated by the program with known biologic pathways. It should be noted here that the interactions presented in the networks are not specific for the retina or brain tissue, as the database contains literature from many different research areas. If the mRNA expression levels of many proteins present in one proposed network have actually been found to be changed, it is likely that they are connected with each other and that their changes may represent a response to the lack of Egr-1.

Real-time RT–PCR: Based on three networks found in the homozygous Egr-1 knockout mice computed by Ingenuity Pathways Analysis Software (hm/30 versus hm/42, see Figure 1A-C), nine genes were chosen for further validation of their expression changes by real-time RT–PCR (three genes per network). For network A we chose: A kinase anchor protein 9 (Akap9), SET domain, bifurcated 1 (Setdb1) and staphylococcal nuclease domain containing 1 (Snd1). The three genes representing network B were: corticotropin releasing hormone (Crh), insulin-like growth factor binding protein 3 (Igfbp3), and LIM and SH3 protein 1 (Lasp1). Finally, from network C we chose: nuclear prelamin A recognition factor (Narf), oxoglutarate dehydrogenase (Ogdh), and selenium binding protein 1 (Selenbp1). In addition, protocadherin-beta 9 (Pcdhb9), the gene that showed the highest fold-change in mRNA expression levels in a comparison between wild-type and knockout mice, was tested with real-time PCR.

The primer sequences, product lengths, NCBI accession numbers and network classifications of the genes tested are shown in Table 1. From each sample, 1 µg of RNA was reverse transcribed using M-MLV reverse transcriptase (Promega, Mannheim, Germany), 500 ng oligo (dT)15 primer and 50 ng of a random primer mixture (Invitrogen, Solingen, Germany). Semiquantitative real-time RT–PCR was performed with the aid of QuantiTect SYBR Green master mix kit of Qiagen on the iCycler iQ Multicolor Real-Time PCR Detection System from Bio-Rad (Hercules, CA). All samples were analyzed in triplicate with a template amount corresponding to 2 ng of RNA. Hypoxanthine-phosphoribosyl-transferase (HPRT) was used as a housekeeping gene and all PCR products were subjected to automated sequencing to ensure amplification of the correct sequences.

Statistics and data analysis: Data were analyzed using the software JMP 5.1 (SAS Institute, Cary, NC) and Excel (Microsoft Corporation, Redmond, WA). The mean cycle threshold (Ct) value of each triplet was taken and the mean normalized expression (MNE) was computed as previously described [33]. To test for differences between the four groups (wt/30, wt/42, hm/30, hm/42), ANOVA’s (ANOVA) were applied for each gene. In case the ANOVA was significant (p<0.05), a paired Student’s t-test was applied as a post-hoc test to test for differences between wt/30 versus wt/42 and hm/30 versus hm/42.

RESULTS

Microarray:
Age-related comparisons (wt/30 versus wt/42) in wild-type mice—Comparing mRNA expression levels between the 30 days old and the 42 days old wild-type mice, 54 genes were classified as differentially expressed (with a minimum FC of ±1.5 and a p-value lower than 0.05). The corresponding genes are listed in Appendix 1 together with the fold-changes and p-values that were determined in homozygous Egr-1 knockout mice at the two ages. Seventeen genes showed reduced mRNA expression in the 42 days old wild-type mice compared to the 30 days old mice. Thirty-seven genes were higher expressed. The maximum fold-changes were −2.40 and 2.62, respectively.
Figure 1. Networks predicted by Ingenuity Pathway Analysis in the homozygous Egr-1 knockout mice. Networks proposed by Ingenuity Pathways Analysis Software. All genes whose mRNA expression levels were found to be differentially regulated in the knockout mice between the age of 30 days and 42 days are highlighted in gray. Encircled are those genes that were chosen for validation by real-time RT–PCR. A detailed legend describing the symbols used in this scheme is enclosed in the figure. Asterisks denote changes in gene expression that were validated using real-time PCR.
Age-related comparisons (hm/30 versus hm/42) in Egr-1 knockout mice: Two hundred fifteen genes had changed their expression levels in the homozygous Egr-1 knockout mice between the age of 30 and 42 days (see Appendix 2 for a list of those genes). Higher mRNA expression was found in 176 genes at 42 days, compared to 30 days, while 39 genes showed reduced mRNA expression. Age-dependent changes in gene expression ranged here between 2.49 fold and −4.01 fold. A pathway analysis was performed based on this list of differentially expressed genes. Genes that were further studied using semiquantitative real-time RT–PCR are shown in bold in Appendix 2.

Eight genes were differently expressed at the two ages in both wild-type and homozygous Egr-1 knockout mice (shown in italics and underlined in Appendix 1 and Appendix 2). The directions of their changes were the same in wild-type- and homozygous Egr-1 knockout mice.

Egr-1-related comparisons (wt/30 versus hm/30 and wt/42 versus hm/42): In the 30 days old mice, the lack of Egr-1 was associated with different mRNA expression levels of 73 genes, with 39 upregulated and 34 downregulated (wt/30 versus hm/30, see Table 2 for a list of those genes). In the 42 days old mice, 135 genes were differently expressed compared to the wild-type. One hundred and thirteen genes were upregulated, and 22 genes were downregulated (wt/42 versus hm/42, see Table 3 for a list of those genes).

Thirty genes showed up in both lists (shown in italics and underlined in both Table 2 and Table 3) and except for one gene (dystrophin (DMD)), the regulation of mRNA expression levels was in the same direction at both 30 days and 42 days. The gene that showed the highest difference in mRNA expression levels (Pcdhb9, shown in bold in Table 2 and Table 3), was further studied using semiquantitative real-time RT–PCR.

Pathway analyses: Data obtained by comparison of the mRNA expression patterns in the homozygous Egr-1 knockout mice between the age of 30 days and 42 days (hm/30 versus hm/42, see Appendix 2, 215 genes) were analyzed using the software “Ingenuity Pathway Analysis.” Several networks were identified that could be involved in retinal signaling. We chose three networks that appeared different in the homozygous Egr-1 knockout mice (see Figure 1A-C) to find candidates for validation by real-time RT–PCR. Networks proposed by the software were common signaling pathways. All genes that were found to be differently expressed in the knockout mice are indicated by filled gray symbols in Figure 1. Genes labeled as open symbols represent intermediate metabolic steps, determined from the current literature by the software. Molecules represented in network A (Figure 1A) are regulated by mitogen-activated protein kinases (MAPK), which respond to a variety of extracellular stimuli and regulate various cellular activities, such as gene expression, mitosis, differentiation, and cell survival/apoptosis [34]. These kinases seem to be effector proteins in network B (Figure 1B) as well, together with insulin, the early response transcription factor activator-protein 1 (Ap1) and another ubiquitous transcription factor, nuclear factor-kappa B (NfkB). The central molecules in network C (Figure 1C) are retinoic acid, vascular endothelial growth factor A (Vegf-A), V-fos FBJ murine osteosarcoma viral oncogene homolog (Fos) and beta-estradiol.

Furthermore, several pathways were identified in both the wild-type and the homozygous knockout mice (wt/30 versus wt/42 and hm/30 versus hm/42, shown in Table 4). The lack of Egr-1 seems to affect a variety of pathways and many fundamental pathways are part of this list (e.g., synaptic long-term depression and potentiation, PDGF- and chemokine signaling, and others).

Real-time RT–PCR: Based on the three networks identified by Ingenuity Pathways Analysis Software (hm/30 versus hm/42, Figure 1A-C), nine genes were chosen for validation of their changes in mRNA expression by real-time RT–PCR, with three genes present in each network. In addition, protocadherin-beta 9 (Pcdhb9), the gene that showed the highest fold-change in comparison between the wild-type and

| Gene   | NCBI accession number | Forward primer (5′-3′) | Reverse primer (5′-3′) | Amplicon | Network |
|--------|-----------------------|------------------------|------------------------|----------|---------|
| Akap9  | NM_194462.2           | GTTGGTGGGATGAGGAGGAG   | GGTAGGCTGAGCAGGTATG    | 173 bp   | A       |
| Seah1  | NM_018877.2           | CATACCTCAGTGTGAGGAGG   | CTGCCACACACCTCTCAAC    | 143 bp   | A       |
| Snd1   | NM_019776.2           | CCTCCTGAGGAGGAGGCTA    | CACACACACCTCTCAAC      | 171 bp   | A       |
| Chh    | NM_205769.1           | CATTCTGAGGAGGAGGCTA    | CTCTCAGACACAAATTTGACC  | 116 bp   | B       |
| Igf2r3 | NM_008343.2           | TCTCCTGCTCCTCTCAA      | CCTCGAGGACCGGCTCC      | 194 bp   | B       |
| Lasp1  | NM_010688.3           | ATACCCATGAGGAGGAGGAG   | ACCATAGGACAGGCTACATCT  | 196 bp   | B       |
| Narf   | NM_026727.2           | CATAGATCCCTCAGACUCCT   | TTCTCAAAACCCCTTATCCCT  | 156 bp   | C       |
| Ogil   | NM_010956.3           | CTCTGTCCTCCTCTGACTG    | AACTTACCTACTGCTTGC     | 184 bp   | C       |
| Selenpl| NM_099150.3           | CTCGCAAAGTGAGCAGTCTT   | CTGATCCACACACCTCTCT    | 161 bp   | C       |
| Pcdhb9 | NM_053134.2           | TTAGAGGAGAAACTCTCTTGTC | TAGGATATGAAGTGCTTGG    | 195 bp   | none    |
| HRPT   | NM_013556.2           | CCAGTAAATTTAGCAGGTGTT  | GATAAAGGACAATCTCAGAG   | 179 bp   | none    |

Shown are the NCBI accession numbers, primer sequences, product sizes and the assignment to the networks of the genes that were further tested with real-time RT–PCR.

Table 1. Description of primers.
**Table 2. List of genes that were differentially expressed between wild-type and homozygous EGR-1 knockout mice at the age of 30 days (WT/30 versus hm/30).**

| Affymetrix ID | Gene symbol | Gene title | FC (wt/p30 vs hm/p30) | p-value (wt/p30 vs hm/p30) | FC (wt/p42 vs hm/p42) | p-value (wt/p42 vs hm/p42) |
|---------------|-------------|------------|------------------------|---------------------------|------------------------|---------------------------|
| 1438686_at    | Eif4g1      | eukaryotic translation initiation factor 4, gamma 1 | −1.71                   | 0.0207                    | −1.15                   | 0.1370                    |
| 1417590_at    | Cyp27a1     | cytochrome P450, family 27, subfamily a, polypeptide 1 | 1.54                    | 0.0047                    | −1.09                   | 0.5424                    |
| 1418306_at    | Crybb1      | crystallin, beta B1 | −1.98                   | 0.0291                    | −1.40                   | 0.5518                    |
| 1419011_at    | Cryba2      | crystallin, beta A2 | −2.02                   | 0.0236                    | −1.92                   | 0.3953                    |
| 1422477_at    | Cables1     | Cdk5 and Abl enzyme substrate 1 | 1.57                    | 0.0067                    | 1.03                    | 0.8213                    |
| 1423062_at    | Igfbp3      | insulin-like growth factor binding protein 3 | 2.05                    | 0.0281                    | −1.09                   | 0.6077                    |
| 1421138_a_at  | Pkb         | protein kinase inhibitor beta | −1.63                   | 0.0356                    | −1.16                   | 0.2212                    |
| 1445710_x_at  | Duxbl       | double homeobox B-like | 1.82                    | 0.0010                    | 1.19                    | 0.4352                    |
| 1417065_at    | Egr1        | early growth response 1 | 1.99                    | 0.0000                    | 1.79                    | 0.0004                    |
| 1417930_at    | Nab2        | Nodl-A binding protein 2 | −2.40                   | 0.0035                    | −2.88                   | 0.0001                    |
| 1428538_s_at  | Rares2      | retinoic acid receptor responder (tazarotene induced) 2 | 1.52                    | 0.0401                    | −1.02                   | 0.9101                    |
| 1430295_at    | Gna13       | guanine nucleotide binding protein, alpha 13 | 1.68                    | 0.0012                    | 1.08                    | 0.4900                    |
| 1434447_at    | Met         | met proto-oncogene | 1.69                    | 0.0380                    | −1.17                   | 0.1753                    |
| 1418552_at    | Opn1sw      | opsin 1 (cone pigments), short-wave-sensitive | −1.72                   | 0.0000                    | −1.40                   | 0.0233                    |
| 1443823_s_at  | Atp1a2      | solute carrier family 6, member 13 | 1.66                    | 0.0068                    | −1.37                   | 0.1628                    |
| 1438945_x_at  | Gapj1       | ATPase, Na+/K+ transporting, alpha 2 polypeptide | 1.76                    | 0.0136                    | −1.09                   | 0.6566                    |
| 1436044_at    | Snc7a       | gap junction membrane channel protein alpha 1 | 1.83                    | 0.0229                    | −1.14                   | 0.5575                    |
| 1415844_at    | Sut4        | sodium channel, voltage-gated, type VII, alpha | −1.59                   | 0.0005                    | −1.74                   | 0.0000                    |
| 1452839_at    | Dph5        | DPH5 homolog (S. cerevisiae) | 1.51                    | 0.0197                    | 1.25                    | 0.0094                    |
| 1440926_at    | Flt1        | FMS-like tyrosine kinase 1 | 1.56                    | 0.0263                    | −1.18                   | 0.2562                    |
| 1428987_at    | Dynlrb2     | dynein light chain rodblock-type 2 | 1.62                    | 0.0199                    | 1.49                    | 0.2117                    |
| 1449623_at    | Tsimd3      | thioredoxin reductase 3 | 1.64                    | 0.0080                    | 1.07                    | 0.6259                    |
| 1417024_at    | Hars        | histidyl-tRNA synthetase | 1.66                    | 0.0000                    | 1.66                    | 0.0000                    |
| 1440179_x_at  | Ibtk1       | IBR domain containing 1 | 1.70                    | 0.0067                    | −1.10                   | 0.1262                    |
| 1455385_at    | Exoc6       | exocyst complex component 6 | 1.76                    | 0.0093                    | 1.09                    | 0.6328                    |
| Affymetrix ID | Gene symbol | Gene title | FC (wt/p30 vs hm/p30) | p-value (wt/ p30 vs hm/ p30) | FC (wt/p42 vs hm/p42) | p-value (wt/ p42 vs hm/ p42) |
|---------------|-------------|------------|-----------------------|-------------------------------|-----------------------|-------------------------------|
| 1454713_s_at  | Hdc         | histidine decarboxylase | 1.80                   | 0.0150                        | 1.21                   | 0.0278                        |
| 1449106_at    | Gpx3        | glutathione peroxidase 3 | 1.93                   | 0.0472                        | 1.28                   | 0.2441                        |
| 1452975_at    | Aox211      | alamine-glyoxylate aminotransferase 2-like 1 | 2.29                   | 0.0072                        | 1.24                  | 0.1606                        |
| 1424325_at    | Esco1       | establishment of cohesion 1 homolog 1 (S. cerevisiae) | −1.53                  | 0.0239                        | −1.22                   | 0.1796                        |
| 1430996_at    | Etk1        | ethenolamine kinase 1 | −1.53                   | 0.0076                        | −1.13                   | 0.4668                        |
| 1441486_at    | Fkbp15      | FK506 binding protein 15 | −1.54                  | 0.0040                        | −1.38                   | 0.1085                        |
| 1434734_at    | E130016E03Rik | RIKEN cDNA E130016E03 gene | −1.57                  | 0.0446                        | −1.00                   | 0.9955                        |
| 1458363_at    | Zdhc17      | zinc finger, DHHC domain containing 17 | −1.58                  | 0.0012                        | −1.25                   | 0.0814                        |
| 1440553_at    | Mecl        | mitochondrial trans-2-enoyl-CoA reductase | −1.58                  | 0.0262                        | −1.16                   | 0.1769                        |
| 1445632_at    | Ogdh        | oxogutarate dehydrogenase (Ipoomide) | −1.58                  | 0.0050                        | 1.09                   | 0.6322                        |
| 1440351_at    | Brca4       | Brca4 | −1.75                  | 0.0283                        | 1.02                   | 0.8804                        |
| 1457732_at    | Pcmtd2      | Protein-L-isoaspartate O-methyltransferase domain containing 2 | −2.00                  | 0.0016                        | −1.01                   | 0.9495                        |
| 1439843_at    | Camk4       | calcium/calmodulin-dependent protein kinase IV | −2.19                  | 0.0000                        | −1.95                   | 0.0006                        |

**Binding (24)**

| Affymetrix ID | Gene symbol | Gene title | FC (wt/p30 vs hm/p30) | p-value (wt/ p30 vs hm/ p30) | FC (wt/p42 vs hm/p42) | p-value (wt/ p42 vs hm/ p42) |
|---------------|-------------|------------|-----------------------|-------------------------------|-----------------------|-------------------------------|
| 1438295_at    | Glccl1      | Glucocorticoid induced transcript 1 | 1.50                   | 0.0044                        | 1.21                   | 0.2239                        |
| 1441317_x_at  | Jakmip1     | janus kinase and microtubule interacting protein 1 | 1.50                   | 0.0256                        | 1.04                   | 0.5407                        |
| 1434203_at    | Fam107a     | Fam107a family with sequence similarity 107, member A | 1.52                   | 0.0244                        | −1.07                   | 0.4713                        |
| 1451602_at    | Snx6        | sorting nexin 6 | 1.55                  | 0.0456                        | 1.06                   | 0.6713                        |
| 1428942_at    | Mlt2        | metallothionein 2 | 1.57                  | 0.0008                        | −1.30                   | 0.0078                        |
| 1435386_at    | Vwif        | Von Willebrand factor homolog | 1.60                   | 0.0158                        | 1.31                   | 0.0166                        |
| 1452217_at    | Atnak       | AHNAC nucleoprotein (desmyoykin) | 1.61                   | 0.0073                        | −1.01                   | 0.9348                        |
| 1422660_at    | LOC671237   | similar to Putative DNA-binding protein 3 | 1.62                  | 0.0121                        | −1.04                   | 0.6603                        |
| 1456351_at    | Brd8        | bromodomain containing 8 | 1.67                  | 0.0003                        | 1.66                   | 0.0005                        |
| 1429239_a_at  | Stard4      | SAR-related lipid transfer (START) domain containing 4 | 2.18                  | 0.0020                        | 1.79                   | 0.0295                        |
| 1417580_s_at  | Selenbp1    | selenium binding protein 1 | 2.34                  | 0.0102                        | 1.23                   | 0.0676                        |
| 1431807_at    | Tncoc6      | transmembrane and coiled-coil domains 6 | 4.10                  | 0.0000                        | 2.73                   | 0.0002                        |
| 1422877_at    | Pdcd12      | protocadherin beta 12 | −1.52                 | 0.0070                        | −1.41                   | 0.0010                        |
| 1437694_at    | BB114266    | Expressed sequence BB114266 | −1.53                 | 0.0318                        | −1.13                   | 0.1606                        |
| 1421132_at    | Prv3        | poxvirus receptor-related 3 | −1.56                 | 0.0153                        | 1.02                   | 0.7130                        |
| 1436981_s_at  | Ywhaz       | tyrosine 3-monooxygenase activation protein, zeta | −1.56                 | 0.0024                        | −1.04                   | 0.5712                        |
| 1440632_at    | Pdcd14      | protocadherin beta 4 | −1.57                 | 0.0446                        | −1.58                   | 0.0833                        |
| 1449527_at    | Pdcd7       | protocadherin beta 7 | −1.58                 | 0.0155                        | −1.64                   | 0.0016                        |
| 1430569_at    | Tce9c       | tetratricopeptide repeat domain 9C | −1.58                 | 0.0089                        | −1.02                   | 0.8478                        |
| 1443950_at    | A630042L21Rik | RIKEN cDNA A630042L21 gene | −1.64                 | 0.0345                        | 1.33                   | 0.0600                        |
| 1421953_at    | Crkl        | v-crk sarcoma virus CT10 oncogene homolog (avian)-like | −1.66                 | 0.0216                        | 1.01                   | 0.9614                        |
| Affymetrix ID  | Gene symbol | Gene title                                | FC (wt/p30 vs hm/p30) | p-value (wt/p30 vs hm/p30) | FC (wt/p42 vs hm/p42) | p-value (wt/p42 vs hm/p42) |
|---------------|-------------|-------------------------------------------|-----------------------|----------------------------|-----------------------|----------------------------|
| 1426458_at    | Slmap       | sarcolemma associated protein             | −1.68                 | 0.0164                     | −1.39                 | 0.1939                     |
| 1443315_at    | Dmd         | Dystrophin                                | −2.45                 | 0.0492                     | 1.66                  | 0.0103                     |
| 1422640_at    | Pcdhb9      | protocadherin beta 9                      | −14.34                | 0.0000                     | −17.48                | 0.0000                     |
| Unknown (8)   |             |                                           |                       |                            |                       |                            |
| 1417460_at    | Ifitm2      | interferon induced transmembrane protein 2| 1.53                  | 0.0478                     | −1.03                 | 0.7015                     |
| 1417275_at    | Mal         | myelin and lymphocyte protein, T-cell differentiation protein | 1.59                  | 0.0059                     | 1.16                  | 0.1316                     |
| 1453632_at    | 4930538K18Rik | RIKEN cDNA 4930538K18 gene                | 1.61                  | 0.0215                     | 1.07                  | 0.5032                     |
| 1434817_s_at  | Rprd2       | Regulation of nuclear pre-mRNA domain containing 2 | 1.75                  | 0.0387                     | 1.13                  | 0.2222                     |
| 1460049_s_at  | 1500015O10Rik | RIKEN cDNA 1500015O10 gene                | 1.77                  | 0.0163                     | 1.34                  | 0.3090                     |
| 1447553_x_at  | Ric3        | Resistance to inhibitors of cholinesterase 3 homolog (C. elegans) | −1.56                 | 0.0314                     | 1.33                  | 0.1653                     |
| 1451634_at    | 2810051F02Rik | RIKEN cDNA 2810051F02 gene                | −1.63                 | 0.0438                     | 1.107                 | 0.5203                     |
| 1425909_at    | A130040M12Rik | RIKEN cDNA A130040M12 gene               | −1.90                 | 0.0001                     | −1.67                 | 0.0368                     |
| Not Annotated (2) |            |                                           |                       |                            |                       |                            |
| 1441430_at    |             |                                           | 1.56                  | 0.0106                     | −1.13                 | 0.2617                     |
| 1442733_at    |             |                                           | −1.55                 | 0.0244                     | −1.05                 | 0.7378                     |

Shown are Affymetrix ID, gene symbol, gene title, fold change (FC) and p-values that indicate the differences in mRNA expression levels between the wild-type and the homozygous Egr-1 knockout mice both at the age of 30 days and 42 days. Genes were sorted after GO annotations. Genes that were significantly changed (with a FC > 1.5 and p-value < 0.05) in both the 30 days old mice and the 42 days old mice are shown in italics and are underlined. The gene that showed the highest differences in mRNA expression levels between the homozygous and the wild-type mice (Pcdhb9 shown in bold) was further investigated using real-time PCR.
| Affymetrix ID | Gene symbol | Gene title | FC (wt/p42 vs hm/p42) | p-value (wt/p42 vs hm/p42) | FC (wt/p30 vs hm/p30) | p-value (wt/p30 vs hm/p30) |
|--------------|-------------|------------|----------------------|-----------------------------|----------------------|-----------------------------|
| **Structural Molecule Activity (1)** | | | | | | |
| 1421811_at | Thbs1 | thrombospondin 1 | 2.09 | 0.0195 | 1.06 | 0.7630 |
| **Transporter Activity (4)** | | | | | | |
| 1458916_at | Sk12a6 | Solute carrier family 12, member 6 | 1.61 | 0.0076 | 1.08 | 0.6697 |
| 1457497_at | Syt1 | Synaptotagmin I | 1.64 | 0.0052 | 1.16 | 0.6213 |
| 1433954_at | Scn7a | sodium channel, voltage-gated, type VII, alpha | 1.64 | 0.0052 | 1.28 | 0.0383 |
| 1415854_at | Syt4 | synaptotagmin IV | 2.26 | 0.0000 | 2.55 | 0.0000 |
| **Enzyme Regulator Activity (7)** | | | | | | |
| 1444671_at | Rasal2 | RAS protein activator like 2 | 1.53 | 0.0363 | 1.30 | 0.2962 |
| 1446595_at | Itsn2 | intersectin 2 | 1.53 | 0.0182 | 1.26 | 0.4784 |
| 1440347_at | Scn7a | sodium channel, voltage-gated, type VII, alpha | 1.61 | 0.0194 | 1.12 | 0.1515 |
| 1415844_at | Syt4 | synaptotagmin IV | 2.26 | 0.0000 | 2.55 | 0.0000 |
| **Molecular Transducer Activity (8)** | | | | | | |
| 1444671_at | Rasal2 | RAS protein activator like 2 | 1.53 | 0.0363 | 1.30 | 0.2962 |
| 1446595_at | Itsn2 | intersectin 2 | 1.53 | 0.0182 | 1.26 | 0.4784 |
| 1440347_at | Scn7a | sodium channel, voltage-gated, type VII, alpha | 1.61 | 0.0194 | 1.12 | 0.1515 |
| 1415844_at | Syt4 | synaptotagmin IV | 2.26 | 0.0000 | 2.55 | 0.0000 |
| **Molecular Transducer Activity (8)** | | | | | | |
| 1458469_at | Cblb | Casitas B-lineage lymphoma b | 1.61 | 0.0089 | 1.13 | 0.6019 |
| 1445555_at | Trpm3 | Transient receptor potential cation channel, subfamily M, members 3 | 1.64 | 0.0456 | 1.13 | 0.5703 |
| 1443279_at | Nlk | Nemo like kinase | 1.55 | 0.0307 | 1.09 | 0.7229 |
| 1441498_at | Ppark | Protein tyrosine phosphatase, receptor type, D | 1.57 | 0.0115 | 1.02 | 0.9324 |
| 1441220_at | Mga2 | Membrane associated guanylate kinase, WW and PDZ domain containing 2 | 1.93 | 0.0316 | 1.10 | 0.8184 |
| 142273_at | Stra6 | stimulated by retinoic acid gene 6 | 1.59 | 0.0205 | 1.22 | 0.3171 |
| 1417205_at | Kdelr2 | KDEL (Lys-Asp-Glu-Leu) endoplasmic reticulum protein retention receptor 2 | 1.53 | 0.0027 | 1.14 | 0.3870 |
| **Transcription Regulator Activity (13)** | | | | | | |
| 1441615_at | Cbfal2t2 | core-binding factor, runt domain, alpha subunit 2, translocated to, 2 (human) | 1.53 | 0.0280 | 1.02 | 0.9209 |
| 1445914_at | Nrf1 | Nuclear respiratory factor 1 | 1.543 | 0.0016 | 1.31 | 0.5977 |
| 1441140_at | Rere | Arginine glutamic acid dipeptide (RE) repeats | 1.55 | 0.0021 | 1.27 | 0.3524 |
| 1456866_at | Zhhnx1a | Zinc finger homeobox 1a | 1.56 | 0.0159 | 1.04 | 0.7871 |
| 1439946_at | Me2c | Myocyte enhancer factor 2C | 1.62 | 0.0041 | 1.14 | 0.5653 |
| 1458661_at | Leor | Ligand dependent nuclear receptor corepressor | 1.63 | 0.0265 | 1.04 | 0.9105 |
| 1446953_at | Tcfl4 | Transcription factor 4 | 1.63 | 0.0097 | 1.03 | 0.9567 |
| 1445695_at | Atn1 | Atnax 1 | 1.73 | 0.0110 | 1.40 | 0.3692 |
| 1417065_at | Egrl | early growth response 1 | 1.79 | 0.0004 | 1.99 | 0.0000 |
| 1443511_at | Rora | RAR-related orphan receptor alpha | 1.96 | 0.0294 | 1.18 | 0.5929 |
| 1436329_at | Egr3 | early growth response 3 | 1.51 | 0.0326 | 1.30 | 0.1831 |
| 1443897_at | Ddit3 | DNA-damage inducible transcript 3 | 1.55 | 0.0297 | 1.11 | 0.6698 |
| 1417920_at | Nab2 | Nrgf-A binding protein 2 | 2.88 | 0.0001 | 2.40 | 0.0035 |
| Affymetrix ID | Gene symbol | Gene title                                             | FC (wt/p42 vs hm/p42) | p-value (wt/p42 vs hm/p42) | FC (wt/p30 vs hm/p30) | p-value (wt/p30 vs hm/p30) |
|--------------|-------------|-------------------------------------------------------|-----------------------|---------------------------|-----------------------|---------------------------|
| 1458663_at   | Large       | Like-glycosyltransferase 1.50 0.0298 1.37 0.2474      |                       |                           |                       |                           |
| 1442813_at   | Dgki        | Dicyglycerol kinase, iota 1.53 0.0448 -1.00 0.9982    |                       |                           |                       |                           |
| 1435273_at   | Wars2       | tryptophanyl tRNA synthetase 2 (mitochondrial) 1.53 0.0008 1.10 0.6011 |                       |                           |                       |                           |
| 1443445_at   | Diap3       | Diaphanous homolog 3 (Drosophila) 1.61 0.0162 -1.32 0.0682 |                       |                           |                       |                           |
| 1442163_at   | Hace1       | HECT domain and ankyrin repeat containing, E3 ubiquitin protein ligase 1 1.64 0.0043 -1.11 0.7030 |                       |                           |                       |                           |
| 1440666_at   | Hars        | histidyl-tRNA synthetase 1.66 0.0000 1.66 0.0000      |                       |                           |                       |                           |
| 1445395_at   | Prkca       | Prokinase C, alpha 1.69 0.0030 1.04 0.9369           |                       |                           |                       |                           |
| 1439540_at   | March2      | membrane-associated ring finger (C3HC4) 2 1.52 0.0115 -1.40 0.0493 |                       |                           |                       |                           |
| 1446412_at   | Wwox        | WW domain-containing oxidoreductase 1.76 0.0152 1.104 0.6550 |                       |                           |                       |                           |
| 1445188_at   | Gphn        | Gephyrin 1.80 0.0010 -1.13 0.7227                   |                       |                           |                       |                           |
| 1445905_at   | Ube2b       | ubiquitin-conjugating enzyme E2B, RAD6 homology (S. cerevisiae) 1.52 0.0099 -1.33 0.2071 |                       |                           |                       |                           |
| 1445773_at   | Nup12       | nucleoporin 2 like 1.51 0.0362 -1.07 0.6814          |                       |                           |                       |                           |
| 1441373_at   | Msr2        | Musashi homolog 2 (Drosophila) 1.53 0.0046 1.14 0.6634 |                       |                           |                       |                           |
| 1446382_at   | Zbtb1L2     | zinc finger and BTB domain containing 12 1.54 0.0359 -1.18 0.1262 |                       |                           |                       |                           |
| 1445030_at   | Phf14       | PHD finger protein 14 1.54 0.0178 1.07 0.8732        |                       |                           |                       |                           |
| 1443599_at   | Lrc2h       | Leucine-rich repeats and calponin homology (CH) domain containing 3 1.55 0.0347 -1.29 0.2964 |                       |                           |                       |                           |
| 1443337_at   | Grip1       | Glutamate receptor interacting protein 1 1.55 0.0323 -1.30 0.5147 |                       |                           |                       |                           |
| 1447615_at   | Fmn1        | Formin 1 1.55 0.0323 -1.30 0.5147                    |                       |                           |                       |                           |
| 1447381_at   | Cpsf6       | Cleavage and polyadenylation specific factor 6 1.51 0.0298 1.12 0.5466 |                       |                           |                       |                           |
| 1445773_at   | Nup12       | nucleoporin 2 like 1.51 0.0362 -1.07 0.6814          |                       |                           |                       |                           |
| 1443731_at   | Msi2        | Musashi homolog 2 (Drosophila) 1.53 0.0046 1.14 0.6634 |                       |                           |                       |                           |
| 1443682_at   | Zbtb1L2     | zinc finger and BTB domain containing 12 1.54 0.0359 -1.18 0.1262 |                       |                           |                       |                           |
| 1445030_at   | Phf14       | PHD finger protein 14 1.54 0.0178 1.07 0.8732        |                       |                           |                       |                           |
| 1443599_at   | Lrc2h       | Leucine-rich repeats and calponin homology (CH) domain containing 3 1.55 0.0347 -1.29 0.2964 |                       |                           |                       |                           |
| 1443337_at   | Grip1       | Glutamate receptor interacting protein 1 1.55 0.0323 -1.30 0.5147 |                       |                           |                       |                           |
| 1447615_at   | Fmn1        | Formin 1 1.55 0.0323 -1.30 0.5147                    |                       |                           |                       |                           |
| 1445893_at   | Rsps2       | R-spondin 2 homolog (Xenopus laevis) 1.55 0.0419 1.09 0.5464 |                       |                           |                       |                           |
| 1442679_at   | Negr1       | Neuronal growth regulator 1 1.58 0.0314 1.02 0.9288 |                       |                           |                       |                           |
| 1445329_at   | Dnkb       | dystrobrevin, beta 1.58 0.0214 -1.07 0.7944           |                       |                           |                       |                           |
| 1444384_at   | Jazf1       | JAZF zinc finger 1 1.58 0.0358 -1.34 0.2980          |                       |                           |                       |                           |
| 1443123_at   | Phf21a      | PHD finger protein 21A 1.60 0.0102 -1.14 0.6756       |                       |                           |                       |                           |
| 1441769_at   | Az15        | ADP-ribosylation factor-like 15 1.61 0.0200 -1.03 0.9351 |                       |                           |                       |                           |
| 1442411_at   | Glc31       | Glucocorticoid induced transcript 1 1.63 0.0068 -1.16 0.6206 |                       |                           |                       |                           |
| 1440551_at   | Dnajc1      | DnaJ (Hsp40) homolog, subfamily C, member 1 1.66 0.0280 1.21 0.5996 |                       |                           |                       |                           |
| 1440543_at   | D930036F22Rik | RIKEN cDNA D930036F22 gene 1.66 0.0428 -1.02 0.9482 |                       |                           |                       |                           |
| 1443315_at   | Dmd         | Dystrophin 1.66 0.0103 -2.45 0.4922                    |                       |                           |                       |                           |
| 1456351_at   | Brx8        | bromodomain containing 8 1.66 0.0005 1.67 0.0003      |                       |                           |                       |                           |
| 1446481_at   | Apbb2       | Amyloid beta (A4) precursor protein-binding, family B, member 2 1.68 0.0279 1.06 0.8385 |                       |                           |                       |                           |
Table 3. Continued.

| Affymetrix ID | Gene symbol | Gene title | FC (wt/p42 vs hm/p42) | p-value (wt/ p42 vs hm/ p42) | FC (wt/p30 vs hm/p30) | p-value (wt/ p30 vs hm/ p30) |
|---------------|-------------|------------|------------------------|-------------------------------|------------------------|-------------------------------|
| 1458263_at    | Cugbp2      | CUG triplet repeat, RNA binding protein 2 | 1.74                      | 0.0041                        | −1.10                  | 0.8176                        |
| 1440067_at    | Ncam1       | Neural cell adhesion molecule 1         | 1.75                      | 0.0171                        | 1.03                   | 0.9102                        |
| 1444888_at    | Cadps       | Ca<2+>-dependent activator protein for secretion | 1.76                      | 0.0054                        | 1.01                   | 0.9801                        |
| 1441330_at    | Grb1        | | 1.99                      | 0.0124                        | −1.12                   | 0.4163                        |
| 1429239_a_at  | Stard4      | STAR-related lipid transfer (START) domain containing 4 | 2.18                      | 0.001991                      | 1.79                   | 0.0295                        |
| 1451692_at    | Tmco6       | transmembrane and coiled-coil domains 6 | 2.73                      | 0.0002                        | 2.10                   | 0.000                         |
| 1449548_at    | Efnb2       | ephrin B2                                  | −1.58                     | 0.0436                        | −1.05                  | 0.8291                        |
| 1449527_at    | Pcdhb7      | protocadherin beta 7                      | −1.64                     | 0.0016                        | −1.58                  | 0.0155                        |
| 1422640_at    | Pcdhb9      | protocadherin beta 9                      | −17.48                    | 0.0000                        | −14.34                 | 0.0000                        |
| Unknown (43)  |             | |                        |                              |                        |                              |
| 1454397_at    | 4632418H02Rik| RIKEN cDNA 4632418H02 gene               | 1.50                      | 0.0066                        | −1.05                  | 0.8725                        |
| 1432713_at    | 6430709C05Rik| RIKEN cDNA 6430709C05 gene               | 1.51                      | 0.0031                        | −1.05                  | 0.8923                        |
| 1442509_at    | Ev15        | Ecotropic viral integration site 5       | 1.52                      | 0.0156                        | −1.03                  | 0.9005                        |
| 1429000_at    | 5330406M23Rik| RIKEN cDNA 5330406M23 gene               | 1.52                      | 0.0119                        | 1.12                   | 0.8002                        |
| 1444651_at    | LOC553089   | hypothetical LOC553089                  | 1.53                      | 0.0230                        | −1.42                  | 0.3710                        |
| 1459409_at    | Cede109a    | coiled-coil domain containing 109A       | 1.53                      | 0.0337                        | 1.01                   | 0.9616                        |
| 1440570_at    | Lhfp13      | Lipoma HMGIC fusion partner-like 3       | 1.53                      | 0.01572                       | 1.29                   | 0.4440                        |
| 1430195_at    | 2810043O03Rik| RIKEN cDNA 2810043O03 gene               | 1.54                      | 0.0153                        | −1.16                  | 0.7564                        |
| 1438788_at    | D5Wsu152e   | DNA segment, Chr 5, Wayne State University 152 | 1.54                      | 0.0060                        | 1.15                   | 0.7128                        |
| 1444137_at    | A430108G06Rik| RIKEN cDNA A430108G06 gene               | 1.54                      | 0.0017                        | 1.03                   | 0.8671                        |
| 1457781_at    | Kcnq1a01    | KCNQ1 overlapping transcript 1          | 1.54                      | 0.0113                        | −1.00                  | 0.9983                        |
| 1430096_at    | 2900017F05Rik| RIKEN cDNA 2900017F05 gene               | 1.56                      | 0.0160                        | 1.14                   | 0.5974                        |
| 1443088_at    | 9930031P18Rik| RIKEN cDNA 9930031P18 gene               | 1.56                      | 0.0026                        | 1.16                   | 0.7326                        |
| 1458706_at    | 2610035D17Rik| RIKEN cDNA 2610035D17 gene               | 1.56                      | 0.0048                        | −1.08                  | 0.5992                        |
| 1453706_at    | 2900042A17Rik| RIKEN cDNA 2900042A17 gene               | 1.57                      | 0.0272                        | 1.02                   | 0.9373                        |
| 1443489_at    | Vps13       | Vacuolar protein sorting 13B (yeast)    | 1.57                      | 0.0012                        | 1.01                   | 0.9575                        |
| 1440604_at    | 8030494B02Rik| Riken cDNA 8030494B02 gene               | 1.57                      | 0.0255                        | −1.35                  | 0.2507                        |
| 1444445_at    | C77648      | expressed sequence C77648               | 1.57                      | 0.0475                        | −1.10                  | 0.6343                        |
| 1433837_at    | 843048G22Rik| RIKEN cDNA 843048G222 gene               | 1.57                      | 0.0226                        | −1.00                  | 0.9943                        |
| 1457508_at    | C43003N24Rik| RIKEN cDNA C43003N24 gene               | 1.60                      | 0.0022                        | −1.34                  | 0.3974                        |
| 1454558_at    | 5430416B10Rik| RIKEN cDNA 5430416B10 gene              | 1.60                      | 0.0256                        | −1.07                  | 0.8665                        |
| 1440892_at    | BC017647    | CDNA sequence BC017647                  | 1.63                      | 0.0403                        | −1.06                  | 0.8572                        |
| 1441467_at    | Tspan5      | Tetraspanin 5                           | 1.64                      | 0.0438                        | −1.10                  | 0.6658                        |
| 1460101_at    | NRXN3       | Neurexin 3                              | 1.67                      | 0.0353                        | −1.05                  | 0.9144                        |
| 1444109_at    | C130009A20Rik| RIKEN cDNA C130009A20 gene              | 1.67                      | 0.0109                        | 1.01                   | 0.9683                        |
| 1454424_at    | 2610040L17Rik| RIKEN cDNA 2610040L17 gene              | 1.68                      | 0.0058                        | 1.06                   | 0.8692                        |
| 1433266_at    | 2810416A17Rik| RIKEN cDNA 2810416A17 gene             | 1.66                      | 0.0005                        | −1.14                  | 0.7660                        |
| 1442561_at    | Mamdc1      | MAM domain containing 1                 | 1.69                      | 0.0020                        | −1.06                  | 0.8040                        |
| 1453906_at    | Med13l      | mediator complex subunit 13-like        | 1.69                      | 0.0010                        | 1.02                   | 0.9415                        |
| 1443201_at    | Gpsi6       | Glypican 6                              | 1.70                      | 0.0288                        | −1.20                  | 0.6594                        |
| Affymetrix ID | Gene symbol | Gene title | FC (wt/p42 vs hm/p42) | p-value (wt/p42 vs hm/p42) | FC (wt/p30 vs hm/p30) | p-value (wt/p30 vs hm/p30) |
|--------------|-------------|------------|-----------------------|-----------------------------|-----------------------|-----------------------------|
| 1458309_at   | Dip2c       | disco-interacting protein 2 homolog C | 1.73                  | 0.0250                     | 1.04                  | 0.8794                      |
| 1458505_at   | LOC552901   | hypothetical LOC552901                  | 1.75                  | 0.0206                     | 1.20                  | 0.5693                      |
| 1429977_at   | 9030425L15Rik | RIKEN cDNA 9030425L15 gene               | 1.76                  | 0.0068                     | 1.07                  | 0.9202                      |
| 1440513_at   | C80258      | expressed sequence C80258                | 1.79                  | 0.0100                     | 1.20                  | 0.6384                      |
| 1429870_at   | C630040K21Rik | RIKEN cDNA C630040K21 gene               | 1.79                  | 0.0029                     | 1.01                  | 0.9797                      |
| 1446102_at   | D9End292e   | DNA segment, Chr 9, ERATO Doi 292, expressed | 1.81                  | 0.0028                     | 1.23                  | 0.2711                      |
| 1458779_at   | 8030445P17Rik | RIKEN cDNA 8030445P17 gene              | 1.83                  | 0.0154                     | 1.17                  | 0.763599                    |
| 1453897_at   | C030014A21Rik | RIKEN cDNA C030014A21 gene              | 1.85                  | 0.0025                     | 1.46                  | 0.265201                    |
| 1446606_at   | LOC625175   | hypothetical protein A630054D14         | 1.86                  | 0.0062                     | 1.30                  | 0.187229                    |
| 1432757_at   | 2900011L18Rik | RIKEN cDNA 2900011L18 gene              | 1.90                  | 0.0232                     | 1.30                  | 0.623096                    |
| 1441231_at   | LOC100042016 | hypothetical protein LOC100042016     | 1.92                  | 0.0002                     | 1.06                  | 0.840764                    |
| 1439086_at   | A930009L07Rik | RIKEN cDNA A930009L07 gene             | −1.58                 | 0.0294                     | 1.19                  | 0.34015                     |
| 1428909_at   | A130040M12Rik | RIKEN cDNA A130040M12 gene             | −1.62                 | 0.0368                     | −1.90                 | 0.0001                      |

**Not Annotated (12)**

| Affymetrix ID | Gene title | FC (wt/p42 vs hm/p42) | p-value (wt/p42 vs hm/p42) | FC (wt/p30 vs hm/p30) | p-value (wt/p30 vs hm/p30) |
|--------------|------------|-----------------------|-----------------------------|-----------------------|-----------------------------|
| 1446799_at   |            | 1.50                  | 0.0030                      | −1.10                 | 0.8224                      |
| 1443271_at   |            | 1.51                  | 0.0384                      | −1.46                 | 0.3101                      |
| 1441740_at   |            | 1.52                  | 0.0284                      | −1.22                 | 0.5593                      |
| 1443526_at   |            | 1.52                  | 0.0062                      | 1.03                  | 0.9444                      |
| 1458077_at   |            | 1.55                  | 0.0148                      | −1.01                 | 0.9758                      |
| 1445740_at   |            | 1.56                  | 0.0456                      | −1.00                 | 0.9998                      |
| 1435409_at   |            | 1.61                  | 0.0220                      | 1.59                  | 0.0878                      |
| 1439999_at   |            | 1.63                  | 0.0223                      | −1.11                 | 0.7133                      |
| 1443744_at   |            | 1.72                  | 0.0128                      | −1.14                 | 0.7148                      |
| 1444622_at   |            | 1.82                  | 0.0224                      | −1.02                 | 0.9539                      |
| 1457479_at   |            | 1.95                  | 0.0060                      | −1.00                 | 0.9815                      |
| 1459595_at   |            | 2.18                  | 0.0019                      | 1.07                  | 0.8169                      |

Shown are Affymetrix ID, gene symbol, gene title, fold change (FC) and p-values that indicate the differences in gene expression levels between the wild-type and the homozygous Egr-1 knockout mice both at the age of 42 days and 30 days. Genes were sorted after GO annotations. Genes that were significantly changed (with a FC > 1.5 and p-value < 0.05) in both the 42 days old mice and the 30 days old mice are shown in italics and are underlined. The gene that showed the highest differences in mRNA expression levels between the homozygous and the wild-type mice (Pcdhb9 [shown in bold]) was further investigated using real-time PCR.
the knockout mice (wt/30 versus hm/30: 14-fold lower expressed in the homozygous mice and wt/42 versus hm/42: 17-fold lower expressed) was tested with real-time RT–PCR. The changes in mRNA expression levels of four of the genes could be validated (Figure 2). Three of them were chosen based on network C (Narf, Ogdh, and Selenbp1) and the gene which showed the biggest difference in mRNA expression levels between wild-type and knockout mice, Pcdhb9, was also confirmed.

The relative signal intensities obtained by microarray analysis (GC-RMA based, shown are the log transformed mean relative signal intensities ±SD, n=4 each) of all four groups tested are shown in Figure 2, upper graphs. The lower graphs shows the mean MNE-values ±SD obtained by real-time RT–PCR (n=4 each). The results of the ANOVA is indicated in the header of the figures for each gene and the fold-changes (FC) and p values (p) of the un-paired Student’s t-tests as post-hoc tests for the comparisons between the 30 days old mice and the 42 days old mice are shown within the graphs.

Note that the comparison of the Pcdhb9 expression is not between the two age groups, but between homozygous knockout mice and wild-type mice at both time points.

Nuclear prelamin A recognition factor (Narf) was lower expressed in the 42 days old homozygous mice, compared to the 30 days old mice in both the microarray analysis (hm/42 versus hm/30: −1.65 fold, p<0.001) and the real-time PCR experiment (−1.53 fold, p<0.05). The mRNA expression did not differ in the wild-type mice over time in either experiment.

Also Oxoglutarate dehydrogenase (Ogdh) was different only in the homozygous Egr-1 knockout mice and showed no changes in mRNA expression levels over time in the wild-type. Post-hoc analysis confirmed that mRNA expression levels in the 30 day-old homozygous mice was significantly lower, compared to 42 day-old animals (hm/30 versus hm/42: 1.69-fold, with p<0.01 in the MA experiment and 1.51 fold with p<0.01 in the PCR experiment).

The mRNA expression levels of selenium binding protein 1 (Selenbp1) were higher in the 30 days old knockout mice, compared to the 42 days old homozygous mice (hm/42 versus hm/30: −2.52 fold with p<0.001 in the MA experiment and

---

**Table 4. Pathways identified in the wild-type and the homozygous Egr-1 knockout mice by Ingenuity Pathway Analysis Software**

| Pathway                        | Molecules                                      |
|--------------------------------|-----------------------------------------------|
| Pathways detected in wild-type mice (30 days versus 42 days, 54 differentially expressed genes): | | |
| Arachidonic Acid Metabolism    | Gpx3, Cyp2d6, Ptgsa                           |
| Acute Phase Response Signaling | Tnf, Tj, A2m                                  |
| FXR/RXR Activation            | Pon1, Cyp27a                                  |
| Pathways detected in Egr-1 knockout-mice (30 days versus 42 days, 215 differentially expressed genes): | | |
| Synaptic Long-term Depression  | Plcb4, Ipr2, Igf1r, Gna13, Prkca, Prkcb1      |
| Synaptic Long-term Potentiation| Plcb4, Ipr2, Atf2, Prkca, Prkcb1              |
| Huntington’s Disease Signaling | Gnb1, Plcb4, Igf1r, Zdhhc17, Atf2, Prkca, Prkcb1 |
| PDGF Signaling                 | Crkl, Ab1, Prkca, Prkcb1                      |
| Chemokine Signaling            | Plcb4, Ppp1r12b, Prkca, Prkcb1                |
| VDR/RXR Activation            | Igfbp3, Ncoa1, Prkca, Prkcb1                  |
| FGF Signaling                  | Crkl, Fgf11, Atf2, Prkca                      |
| Ephrin Receptor Signaling      | Gnb1, Crkl, Ab1, Gna13, Atf2, Rapgef1         |
| Axonal Guidance Signaling      | Gnb1, Plcb4, Pfn1, Crkl, Ab1, Gna13, Prkca, Prkcb1 |
| Lysine Degradation             | Setdb1, Nsd1, Ogdh                            |
| Actin Cytoskeleton Signaling   | Pfn1, Diaph3, Crkl, Ppp1r12b, Fgf11, Gna13    |
| Circadian Rhythm Signaling    | Arntl, Atf2                                   |
| G-Protein Coupled Receptor Signaling | Pdeo8a, Plcb4, Atf2, Prkca, Prkcb1          |
| Integrin Signaling             | Tspan5, Crkl, Ppp1r12b, Ab1, Rapgef1          |
| Neuregulin Signaling           | Crkl, Prkca, Prkcb1                           |
| SAPK/JNK Signaling             | Gnb1, Crkl, Gna13, Atf2                       |
| ERK/MAPK Signaling             | Crkl, Atf2, Rapgef1, Prkca, Prkcb1            |

Shown are the descriptions of the pathways and the molecules involved in both the wild-type and the homozygous Egr-1 knockout mice that changed their mRNA expression patterns over the investigated period of time (p30 versus p42) based on Ingenuity Pathway Analysis Software.
−2.23 fold with p<0.001 in the PCR experiment) and again, no such changes were observed in the wild-type.

In case of protocadherin-beta 9 (Pcdhb9), mRNA expression levels did not change with age, but were much lower in the knockout mice. Real-time PCR detected a fivefold decline in the expression of Pcdhb9 in knockout mice, both at p30 and at p42, whereas the microarray analysis determined an even larger decline (hm/30 versus wt/30: −14 fold and hm/42 versus wt/42: −17 fold, with p<0.001 each).

**DISCUSSION**

Earlier studies suggested that Egr-1 might play a role in eye growth regulation in chicks [13] and mice [20,35]. The current study attempted to determine which genes were differentially regulated in Egr-1 knockout mice at two different developmental stages. Since Egr-1 knockout mice had longer eyes at age 42 days, compared to wild-type mice, but not at day 30, it was hoped that a correlation could be found between the expression of certain genes and changes in eye growth. Furthermore, it was hoped that some of the changes might occur that relate to genes or factors that are already known to be involved in the regulation of axial eye growth in animal models.

The analysis of retinal gene expression in homozygous Egr-1 knockout mice and wild-type mice at different ages (p30 and p42) provided a huge amount of data. Depending on the comparisons (wild-type versus homozygous, 30 days versus 42 days), different information about gene expression were obtained and different conclusions could be drawn. The focus in this paper was on changes that occur in homozygous Egr-1 knockout mice and wild-type mice between 30 and 42 days (wt/30 versus wt/42 and hm/30 versus hm/42) and are shown within the figures. Please note that in the case of Pcdhb9, the comparison is between the knockout and the wild-type mice at both ages (wt/30 versus hm/30 and wt/42 versus hm/42).

Figure 2. Genes whose mRNA expression levels could be validated by real-time RT–PCR. Mean relative expression values ±SD (n=4) obtained by microarray analysis and mean normalized expression values obtained by real-time PCR (n=4). The p-values of the ANOVA’s can be seen in the heading of the figures. The fold-changes and p-values (determined by un-paired Student’s t-test as post-hoc analysis) were computed for the comparison between 30 days and 42 days old knockout- and wild-type mice (wt/30 versus wt/42 and hm/30 versus hm/42) and are shown within the figures. Please note that in the case of Pcdhb9, the comparison is between the knockout and wild-type mice at both ages (wt/30 versus hm/30 and wt/42 versus hm/42).
enhanced axial eye growth, or represent just epiphenomena, remains undefined and needs to be determined by further studies.

Microarray:

**Gene expression changes over time (p30 versus p42)**

It was not surprising that in wild-type mice only 54 genes showed differential mRNA expression over time (wt/30 versus wt/42, see Appendix 1), since the mouse retina is generally considered to be mature at the age of about p21 [36]. In the homozygous Egr-1 knockout mice, 215 genes (roughly four times as many) were differently expressed (hm/30 versus hm/42, Appendix 2). Eight genes showed similar changes in mRNA expression in both the homozygous and the wild-type Egr-1 knockout mice (shown in italics and underlined in Appendix 1 and Appendix 2). They likely encode for proteins that are involved in normal retinal function and are not related to the abnormal ocular growth in the knockout mice.

The average mean fold-changes in this study were 1.48±0.41, which is in line with findings from other microarray studies [16,19,37,38]. It has to be kept in mind that global gene expression measurements in a heterogeneous tissue like the retina are difficult to interpret since large changes in mRNA expression in a subset of cells might be obscured by changes in the opposite direction in a different, perhaps even more abundant population of cells. For the same reason, large changes in mRNA expression in a rare cell type might go unnoticed because they generate only a small fraction of the total mRNA. In the future, quantitative immunohistochemistry might help to detect changes in gene products which are localized to certain cells types.

**Differences in gene expression in Egr-1 knockout mice and their wild-type**

Thirteen genes were differentially expressed in knockout mice, compared to wild-type, at both ages tested (Table 2 and Table 3: genes are shown in italics and underlined). Except for dystrophin (DMD), the regulation of those genes was in the same direction at both ages. These genes are therefore most probably target genes of Egr-1 and are not directly related to the developmental changes observed in these mice. Nevertheless, these thirteen genes are of interest because they were not previously described as possible targets for the Egr-1 protein. Still, whether the interaction with the Egr-1 protein is direct or indirect, has yet to be experimentally validated using other techniques like chromatin immunoprecipitation. The Egr-1 knockout mice used in our study contain several in-frame stop codons in the Egr-1 coding sequence, upstream of the zinc finger DNA binding domain. Parts of the mRNA sequence of Egr-1 can therefore still be transcribed but the stop-codons lead to the functional elimination of the protein Egr1. The truncated Egr-1 mRNAs can still bind to the microarray. Upregulation of Egr-1 mRNA itself in the knockout mice can be explained by the fact that Egr-1 can suppress its own expression, as has been shown in tissue culture [39]. A negative feedback mechanism has already been described elsewhere and can be seen for Nab2 (Ngfi-A-binding protein-2) [40]. This protein was massively downregulated in Egr-1 knockout mice and is assumed to be a major regulator of Egr-1 function, since it is induced by the same stimuli that induce Egr-1. Dystrophin (DMD) mRNA expression was lower at p30 in the homozygous mice, compared to the wild-type mice, and higher at p42. An enhanced DMD content may therefore be correlated with enhanced axial eye growth. DMD is a plasma membrane-associated cytoskeletal protein of the spectrin superfamily and its absence or functional deficiency is the cause of several types of muscular dystrophies in humans. In some of these patients, retinal function is affected as well, as reflected in a reduced b-wave in the electroretinograms (ERG). DMD isoforms have been localized to Müller cells and photoreceptor terminals, so the abnormality in the ERGs is most likely due to a disturbance of neurotransmission between photoreceptors and ON-bipolar cells [41]. Interestingly, the lack of the dystrophin isoform Dp71 leads to impaired clustering of two Müller glia cell proteins in mice, namely the inwardly rectifying potassium channel Kir4.1 and the water pore aquaporin 4 (AQP4) [42]. Both Kir4.1 and AQP4 have already been implicated in the development of myopia and their role as a conduit for movement of retinal fluid into the vitreous was suggested [43,44].

Protocadherin beta 9 (Pcdhb9) was the most heavily regulated gene in this study (wt/30 versus hm/30: 14-fold downregulated and wt/42 versus hm/42: 17-fold downregulated in the homozygous Egr-1 knockout mice). Protocadherins are calcium-dependent cell–cell adhesion molecules. Their specific functions are unknown, but they most likely play a critical role in the establishment and function of specific cell-cell neural connections [45]. The massive downregulation of this gene suggests a tight control, either directly by Egr-1, or indirectly by other Egr-1-regulated genes.

**Ingenuity pathway analysis**

The list of genes that were differentially expressed in the Egr-1 knockout mice between the age of 30 and 42 days (hm/30 versus hm/42) was analyzed using Ingenuity Pathway Analysis Software. Many ubiquitous signaling pathways in the retina seem to be involved. Therefore, it is difficult to define those genes that are responsible for the development of the relative myopia in the 42-day-old Egr-1 knockout mice. As can be seen in Figures 1A–C, genes that showed altered mRNA expression in this study were not the key regulators in the functional networks proposed by the software. As already mentioned above, these pathway schemes are based on known interactions between molecules. They provide only suggestions for possible interactions. Involvement of the intermediate proteins and co-factors in these pathways is, therefore, possible but not proven. Furthermore, since the changes in mRNA expression levels of any gene chosen from network A and B could not be
were very similar whereas for determined by PCR and MA of but no differences were found between wild-types and knockout mice (Dr. Lukas Rüttiger, Tuebingen Hearing Research Centre [THRC], Tuebingen, Germany, personal communication 2008). Therefore the function of Egr-1 in the regulation of axial eye growth seems to be quite specific despite the fact that common signaling pathways were affected.

Real-time RT–PCR:

Validation of genes—The mRNA expression levels of four out of the ten tested genes could be validated (Figure 2). To be able to compare the relative expression levels as determined by microarray analysis (MA) and real-time PCR (PCR) easily, Figure 2 shows the results of MA and PCR experiments separately for each gene. Non-validated genes are not represented in this figure. The fold-changes determined by PCR and MA of Narf, Ogdh, and Selenbp1 were very similar whereas for Pcdhb9, the magnitude of changes was severely overestimated by MA. Considering this fact, the involvement of network A and B is more questionable, since none of the genes tested with real-time PCR could be validated. On the other hand, only three genes were tested in each network, and others which would have been validated upon testing might have been overlooked. Our primers were designed to bind to the same part of the sequence that was detected by the oligonucleotide probes on the Affymetrix chip (to avoid detection of different isoforms) and should have been appropriate to validate the microarray results. The applied false-discovery-rate of 5% thus does not seem to reflect the true errors that are unavoidable in this technique. These observations confirm that validation of the results of microarray analyses by other techniques (in this case semiquantitative real-time RT–PCR) should be mandatory.

Genes whose transcription could be validated: The functions of the three genes which could be validated with real-time PCR are described in more detail below:

Narf—The expression of Nuclear prelamin A recognition factor was found to be lowest in the 42 days old knockout mice. Prenylation and methylation occurs at the C-terminal end of proteins and was initially believed to be important only for membrane attachment. However, another role for prenylation appears to be the mediation of protein–protein interactions [46]. The only nuclear proteins known to be prenylated in mammalian cells are prelamin A- and B-type lamins. Lamins are fibrous proteins providing structural function and transcriptional regulation in the cell nucleus, but the cellular role of both the prenylated prelamin A precursor and Narf, which is known to bind to the farnesylated prelamin A, is unknown and its role in the retina is unclear.

Ogdh—Oxoglutarate dehydrogenase mRNA expression was significantly enhanced in 42-day-old knockout mice. Ogdh is a mitochondrial enzyme complex, comprising of three different subunits (Ogdh, Dld, Dlst) that converts 2-oxoglutarate into succinyl-CoA and carbon dioxide in the Krebs cycle. Its reduction in patients with Alzheimer disease suggests an altered metabolism of the nervous tissue [47]. Unfortunately, no information is available yet for the role of this enzyme in the retina, but it could well be that the changes in mRNA expression of this gene reflects changes in the metabolic rate of retinal cells in the homozygous Egr-1 knockout mice.

Selenbp1—Egr-1 knockout mice showed a high expression of Selenbp1 at the age of 30 days, with a subsequent decline. Selenium binding protein has been shown in several studies to be downregulated in cancer [48,49]. A protective effect of selenium in preventing macular degeneration has also been shown [50] and another selenium transporter (selenoprotein P) has been found to be upregulated in the retina of chicks that were treated with either positive or negative lenses [51]. Selenbp1 expression can be blocked by TGF-β in smooth muscle cells [52] and this protein (TGF-β) has already been implicated in myopia [53,54] and in the regulation of programmed cell death in the retina [55]. The role of selenium and its associated binding proteins in the retina of Egr-1 knockout mice merits further investigation.

Involvement of network C. Although the genes for which expression changes could be validated belong to this network, the involvement of the “key molecules” presented in Figure 1C remains speculative. No mRNA expression changes of e.g., VEGF, cFos, or EGF were found in this study although oligonucleotides representing mRNAs of VEGF, cFos, EGF, and retinoic acid receptors are present on the Affymetrix chip used in this study. Obviously, the lack of functional Egr-1 protein did not affect mRNA expression levels of these genes. Nevertheless, some of those molecules have already been proposed to play a role in the regulation of eye growth, or were shown to change in the retina in response to various optical stimuli [4-6,13,16,56-62]. The fact that they seem to link several factors that were found to have changed mRNA expression levels in Egr-1 knockout mice is in line with the idea that these molecules are involved in the regulation of eye growth.

Outlook: This study provided a list of genes that appear associated with Egr-1 signaling and/or altered eye growth in Egr-1 knockout mice. It is difficult to define specific roles to those genes in eye growth in the Egr-1 knockout mice. Analysis of possibly involved networks show that the lack of Egr-1 affects common pathways in the retina. Furthermore,
other important factors (like cFos, VEGF, NfkB) may play a role as well, perhaps partially taking over the role of Egr-1 in the retina of Egr-1 knockout mice. We believe that the microarray analysis is a powerful tool to detect NEW candidates, rather than to look at the "usual suspects." It is, however, difficult to use the microarray technology in heterogeneous tissue like retina. There are now advanced methods available to focus on certain cell types (e.g., laser capture microdissection of fluorescent-activated cell sorting). Nevertheless, some interesting genes were found in this study. In addition, several direct or indirect target genes of Egr-1 could be identified, including the most prominently regulated gene protocadherin-beta 9. The list of differentially expressed genes is accessible online in the Gene Expression Omnibus (GEO) Database and might be useful not only to researchers in the field of myopia.

ACKNOWLEDGMENTS

This study was supported by the German Research Foundation, DFG Sch518/13–1. We thank Prof. Dr. Wissinger of the Molecular Genetics Department of the Ophthalmic Research Institute in Tuebingen for sequencing of our samples.

REFERENCE

1. Stone RA, Lin T, Latties AM, Iuvone PM. Retinal dopamine and form-deprivation myopia. Proc Natl Acad Sci USA 1989; 86:704-6. [PMID: 2911600]

2. Iuvone PM, Tigges M, Stone RA, Lambert S, Latties AM. Effects of apomorphine, a dopamine receptor agonist, on ocular refraction and axial elongation in a primate model of myopia. Invest Ophthalmol Vis Sci 1991; 32:1674-7. [PMID: 2016144]

3. Guo SS, Sivak JG, Callender MG, Diehl-Jones B. Retinal dopamine and lens-induced refractive errors in chicks. Curr Eye Res 1995; 14:385-9. [PMID: 7648864]

4. Seko Y, Shimizu M, Tokoro T. Retinoic acid increases in the retina of the chick with form deprivation myopia. Ophthalmic Res 1998; 30:361-7. [PMID: 9371117]

5. Bitzer M, Feldkaemper MP, Schaefelf F. Visually induced changes in components of the retinoic acid system in fundal layers of the chick. Exp Eye Res 2000; 70:97-106. [PMID: 10644425]

6. Mertz JR, Wallman J. Choroidal retinoic acid synthesis: a possible mediator between refractive error and compensatory eye growth. Exp Eye Res 2000; 70:519-27. [PMID: 10866000]

7. Fujii S, Honda S, Sekiya Y, Yamasaki M, Yamamoto M, Sajioh K. Differential expression of nitric oxide synthase isoforms in form-deprived chick eyes. Curr Eye Res 1998; 17:586-93. [PMID: 9663848]

8. Nickla DL, Wilsdof CF. The effect of the nonspecific nitric oxide synthase inhibitor NG-nitro-L-arginine methyl ester on the choroidal compensatory response to myopic defocus in chickens. Optom Vis Sci 2004; 81:111-8. [PMID: 15127930]

9. Nickla DL, Wilken E, Lytle G, Yom S, Mertz J. Inhibiting the transient choroidal thickening response using the nitric oxide synthase inhibitor L-NAME prevents the ameliorative effects of visual experience on ocular growth in two different visual paradigms. Exp Eye Res 2006; 83:456-64. [PMID: 16635488]

10. Stone RA, Latties AM, Raviola E, Wiesel TN. Increase in retinal vasoactive intestinal polypeptide after eyelid fusion in primates. Proc Natl Acad Sci USA 1988; 85:257-60. [PMID: 2448769]

11. Raviola E, Wiesel TN. Neural control of eye growth and experimental myopia in primates. Ciba Found Symp 1990; 155:22-38. [PMID: 2088678]

12. Seltner RL, Stell WK. The effect of vasoactive intestinal peptide on development of form deprivation myopia in the chick: a pharmacological and immunocytochemical study. Vision Res 1995; 35:1265-70. [PMID: 7610586]

13. Fischer AJ, McGuire JJ, Schaefelf F, Stell WK. Light- and focus-dependent expression of the transcription factor ZENK in the chick retina. Nat Neurosci 1999; 2:706-12. [PMID: 10412059]

14. Bitzer M, Schaefelf F. Defocus-induced changes in ZENK expression in the chicken retina. Invest Ophthalmol Vis Sci 2002; 43:246-52. [PMID: 11773038]

15. Fischer AJ, Ritchey ER, Scott MA, Wynne A. Bullwhip neurons in the retina regulate the size and shape of the eye. Dev Biol 2008; 317:196-212. [PMID: 18358467]

16. Brand C, Schaeffel F, Feldkaemper MP. A microarray analysis of retinal transcripts that are controlled by image contrast in mice. Mol Vis 2007; 13:920-32. [PMID: 17653032]

17. Ashby R, McCarthy CS, Maleszka R, Megaw P, Morgan IG. A muscarinic cholinergic antagonist and a dopamine agonist rapidly increase ZENK mRNA expression in the form-deprived chicken retina. Exp Eye Res 2007; 85:15-22. [PMID: 17498696]

18. Ashby RS. Molecular control of eye growth: A candidate gene approach [dissertation]. Canberra (AU): The Australian National University 2007.

19. Schippeit R, Schaefelf F, Feldkaemper MP. Microarray analysis of retinal gene expression in chicks during imposed myopic defocus. Mol Vis 2008; 14:1589-99. [PMID: 18769560]

20. Schippeit R, Burkhardt E, Feldkaemper MP, Schaefelf F. Relative axial myopia in Egr-1 (ZENK) knockout mice. Invest Ophthalmol Vis Sci 2007; 48:11-7. [PMID: 17197510]

21. Virolle T, Krones-Herzig A, Baron V, De Gregorio G, Adamson K. Differential expression of nitric oxide synthase isoforms in the retina of chickens. Exp Eye Res 2000; 70:97-106. [PMID: 10644425]

22. Lee JL, Everitt BJ, Thomas KL. Independent cellular processes for hippocampal memory consolidation and reconsolidation. Science 2004; 304:839-43. [PMID: 15073322]

23. Fu M. Egr-1 target genes in human endothelial cells identified by microarray analysis. Gene 2003; 280:180-20. [PMID: 12556466]

24. Chen SJ, Ning H, Ishida W, Sodin-Semrl S, Takagawa S, Mori Y, Varga J. The early-immediate gene EGR-1 is induced by transforming growth factor-beta and mediates stimulation of collagen gene expression. J Biol Chem 2006; 281:21183-97. [PMID: 1670209]

25. Norton TT, Rada JA. Reduced extracellular matrix in mammalian sclera with induced myopia. Vision Res 1995; 35:1271-81. [PMID: 7610587]
26. McBrien NA, Cornell LM, Gentle A. Structural and ultrastructural changes to the sclera in a mammalian model of high myopia. Invest Ophthalmol Vis Sci 2001; 42:2179-87. [PMID: 11527928]

27. Siegwart JT, Norton TT. The time course of changes in mRNA levels in tree shrew sclera during induced myopia and recovery. Invest Ophthalmol Vis Sci 2002; 43:2067-75. [PMID: 12091398]

28. Khachigian LM, Williams AJ, Collins T. Interplay of Sp1 and Egr-1 in the proximal platelet-derived growth factor A-chain promoter in cultured vascular endothelial cells. J Biol Chem 1995; 270:27679-86. [PMID: 7499234]

29. Khachigian LM, Lindner V, Williams AJ, Collins T. Egr-1 induced endothelial gene expression: a common theme in vascular injury. Science 1996; 271:1427-31. [PMID: 8596917]

30. Biesiada E, Razandi M, Levin ER. Egr-1 activates basic fibroblast growth factor transcription. Mechanistic implications for astrocyte proliferation. J Biol Chem 1996; 271:18576-81. [PMID: 8702507]

31. Baron V, Adamson ED, Calogero A, Ragona G, Mercola D. The transcription factor Egr-1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin. Cancer Gene Ther 2002; 11:309-20. [PMID: 15889015]

32. Lee SL. Luteinizing hormone deficiency and female infertility in mice lacking the transcription factor NGFI-A (Egr-1). Science 1996; 273:1219-21. [PMID: 8703054]

33. Schippert R, Brand C, Schaeffel F, Feldkaemper MP. Changes in scleral MMP-2, TIMP-2 and TGFbeta2 mRNA expression after imposed myopic and hyperopic defocus in chickens. Exp Eye Res 2006; 82:710-9. [PMID: 16289164]

34. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K, Cobb MH. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001; 22:153-83. [PMID: 11294822]

35. Dalton C. Targeted inactivation of dystrophin gene product Dp71: phenotypic impact in mouse retina. Hum Mol Genet 2003; 12:1543-54. [PMID: 12812982]

36. Smith RS, Kao WWY, John SWM. Ocular development. In: Systematic Evaluation of the Mouse Eye: Anatomy, Pathology, and Biopathogens. Boca Raton, London, New York, Washington, D.C.; CRC Press; 2002. p. 45–63.

37. McGlinn AM, Baldwin DA, Tobias JW, Budak MT, Khurana TS, Stone RA. Form-deprivation myopia in chick induces limited changes in retinal gene expression. Invest Ophthalmol Vis Sci 2008; 15:2720-2739 <http://www.molvis.org/molvis/v15/a288> © 2009 Molecular Vision

38. Berman K, Cobb MH. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001; 22:153-83. [PMID: 11294822]

39. Cao X, Mahendran R, Guy GR, Tan YH. Detection and characterization of cellular EGR-1 binding to its recognition site. J Biol Chem 1993; 268:16949-57. [PMID: 8349585]

40. Kumbrik J, Gerlinger M, Johnson JP. Egr-1 induces the expression of its coexpressor nab2 by activation of the nab2 promoter thereby establishing a negative feedback loop. J Biol Chem 2005; 280:42785-93. [PMID: 16260776]

41. Schmitz F, Drenckhahn D. Dystrophin in the retina. Prog Neurobiol 1997; 53:547-60. [PMID: 9421835]

42. Dalloz C. Targeted inactivation of dystrophin gene product Dp71: phenotypic impact in mouse retina. Hum Mol Genet 2003; 12:1543-54. [PMID: 12812982]

43. Goodyear MJ, Junghans BM, Giannarrella L, Murphy MJ, Crewther DP, Crewther SG. A role for aquaporin-4 during induction of form deprivation myopia in chick. Mol Vis 2008; 14:298-307. [PMID: 18334967]

44. Goodyear MJ, Crewther SG, Edwards MH, Junghans BM, Hazi A, Crewther DP. A role for aquaporin-4 (AQP4) channels and inward-rectifying potassium channels (Kir4.1) during refractive compensation to optical defocus. ARVO Annual Meeting; 2007 May 6–10; Fort Lauderdale (FL).

45. Frank M, Klemler R. Protocadherins. Curr Opin Cell Biol 2002; 14:557-62. [PMID: 12231349]

46. Marshall CJ. Protein prenylation: a mediator of protein-protein interactions. Science 1993; 259:1865-6. [PMID: 8456312]

47. Butterworth RF, Besnard AM. Thiamine-dependent enzyme changes in temporal cortex of patients with Alzheimer's disease. Metab Brain Dis 1990; 5:179-84. [PMID: 20827127]

48. Huang KC. Selenium binding protein 1 in ovarian cancer. Int J Cancer 2006; 118:2433-40. [PMID: 16380993]

49. Kim H. Suppression of human selenium-binding protein 1 is a late event in colorectal carcinogenesis and is associated with poor survival. Proteomics 2006; 6:3466-76. [PMID: 16645984]

50. Head KA. Natural therapies for ocular disorders, part one: diseases of the retina. Altern Med Rev 1999; 4:342-59. [PMID: 10559549]

51. Ohnemus C, Buck C, Simon P, Schaeffel F, Feldkaemper MP. Temporal changes of novel transcripts in the chicken retina following imposed defocus. Mol Vis 2004; 10:1019-27. [PMID: 15635295]

52. Torreira J. Selenium-binding protein-1 in smooth muscle cells is downregulated in a rhesus monkey model of chronic allograft nephropathy. Am J Transplant 2005; 5:58-67. [PMID: 15636612]

53. Seko Y, Shimokawa H, Tokoro T. Expression of bFGF and TGF-beta 2 in experimental myopia in chicks. Invest Ophthalmol Vis Sci 1995; 36:1183-7. [PMID: 7730028]

54. Honda S, Fujii S, Sekiya Y, Yamamoto M. Retinal control on the axial length mediated by transforming growth factor-beta in chick eye. Invest Ophthalmol Vis Sci 1996; 37:2519-26. [PMID: 8937668]

55. Dunker N, Schuster N, Kriegstein K. TGF-beta modulates programmed cell death in the retina of the developing chick embryo. Development 2001; 128:1933-42. [PMID: 11493517]

56. Wittmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003; 22:1-29. [PMID: 12597922]

57. Seko Y, Seko Y, Fujikura H, Pang J, Tokoro T, Shimokawa H. Induction of vascular endothelial growth factor after application of mechanical stress to retinal pigment epithelium of the rat in vitro. Invest Ophthalmol Vis Sci 1999; 40:3287-91. [PMID: 10586955]

58. Nguyen KT, Wildsoet C. Long-term effect of induced myopia on vascular endothelial growth factor expression in chick
retinal pigment epithelium. ARVO Annual Meeting; 2009 May 3–7; Fort Lauderdale (FL).

59. Araki CM, Hamassaki-Britto DE. Motion-sensitive neurons in the chick retina: a study using Fos immunohistochemistry. Brain Res 1998; 794:333-7. [PMID: 9622668]

60. Yoshida K, Kawamura K, Imaki J. Differential expression of c-fos mRNA in rat retinal cells: regulation by light/dark cycle. Neuron 1993; 10:1049-54. [PMID: 8318229]

61. McFadden SA, Howlett MH, Mertz JR. Retinoic acid signals the direction of ocular elongation in the guinea pig eye. Vision Res 2004; 44:643-53. [PMID: 14751549]

62. Troilo D, Nickla DL, Mertz JR, Summers Rada JA. Change in the synthesis rate of ocular retinoic acid and scleral glycosaminoglycan during experimentally altered eye growth in marmosets. Invest Ophthalmol Vis Sci 2006; 47:1768-77. [PMID: 16638980]
Appendix 1. List of differentially expressed genes in the wild-type mice between p30 and p42 days (wt/30 versus wt/42).

To access the data, click or select the words “Appendix 1.” This will initiate the download of a (pdf) archive that contains the file. Affymetrix ID, gene symbol, gene title, fold change (FC) and p-values of both the wild-type mice and the homozygous Egr-1 knockout mice are shown. Genes were sorted after GO annotations. Genes that were significantly changed (with a FC > 1.5 and p-value < 0.05) in both the wild-type mice and the homozygous Egr-1 knockout mice are shown in italics and are underlined.

Appendix 2. List of genes that were differentially expressed in the homozygous Egr-1 knockout mice between p30 and p42 (hm/30 versus hm/42).

To access the data, click or select the words “Appendix 2.” This will initiate the download of an Excel (.xls) file that contains the file. Affymetrix ID, gene symbol, gene title, fold change (FC), and p-values of both the homozygous Egr-1 knockout mice and the wild-type mice are shown. Genes were sorted after GO annotations. Genes that were significantly changed (with a FC >1.5 and p-value <0.05) in both the homozygous wild-type mice and the Egr-1 knockout mice are shown in italics and are underlined. Genes that were chosen for real-time RT–PCR validation are shown in bold.